The impact of oral contraceptives and metformin on anti-Müllerian hormone serum levels in women with polycystic ovary syndrome and biochemical hyperandrogenemia

References

• Carmina E, Lobo RA. Polycystic ovary syndrome (PCOS): arguably the most common endocrinopathy is associated with significant morbidity in women. J Clin Endocrinol Metab 1999;84:1897–1899.
   PubMed Web of Science ®Google Scholar
• Urbanek M, Du Y, Silander K, Collins FS, Steppan CM, Strauss JF 3rd, Dunaif A, Spielman RS, Legro RS. Variation in resistin gene promoter not associated with polycystic ovary syndrome. Diabetes 2003;52:214–217.
   PubMed Web of Science ®Google Scholar
• Norman RJ, Dewailly D, Legro RS, Hickey TE. Polycystic ovary syndrome. Lancet 2007;370:685–697.
   PubMed Web of Science ®Google Scholar
• Jonard S, DeWailly D. The follicular excess in polycystic ovaries, due to intra-ovarian hyperandrogenism, may be the main culprit for the follicular arrest. Hum Reprod Update 2004;10:107–117.
   PubMed Web of Science ®Google Scholar
• Durlinger AL, Gruijters MJ, Kramer P, Karels B, Ingraham HA, Nachtigal MW, Uilenbroek JT, Grootegoed JA, Themmen AP. Anti-Müllerian hormone inhibits initiation of primordial follicle growth in the mouse ovary. Endocrinology 2002;143:1076–1084.
   PubMed Web of Science ®Google Scholar
• Durlinger AL, Gruijters MJ, Kramer P, Karels B, Kumar TR, Matzuk MM, Rose UM, de Jong FH, Uilenbroek JT, Grootegoed JA, Themmen AP. Anti-Müllerian hormone attenuates the effects of FSH on follicle development in the mouse ovary. Endocrinology 2001;142:4891–4899.
   PubMed Web of Science ®Google Scholar
• Piouka A, Farmakiotis D, Katsikis I, Macut D, Gerou S, Panidis D. Anti-Müllerian hormone levels reflect the severity of PCOS, but are negatively influenced by obesity: relationship with increased Luteinizing hormone levels. Am J Physiol Endocrinol Metab 2009;296:238–243.
   PubMed Web of Science ®Google Scholar
• Pigny P, Robert Y, Cortet-Rudelli C, Decanter C, Jonard S, DeWailly D. Elevated serum level of antimüllerian hormone in patients with polycystic ovary syndrome: Relationship to the ovarian follicle excess and the follicular arrest. J Clin Endocrinol Metab 2003;88:5957–5962.
   PubMed Web of Science ®Google Scholar
• Pigny P, Jonard S, Robert Y, DeWailly D. Serum antimüllerian hormone as a surrogate for antral follicle count for definition of the polycystic ovary syndrome. J Clin Endocrinol Metab 2006;91:941–945.
   PubMed Web of Science ®Google Scholar
• Siow Y, Kives S, Hertweck P, Perlman S, Fallat ME. Serum müllerian inhibiting substance levels in adolescent girls with normal menstrual cycles or with polycystic ovary syndrome. Fertil Steril 2005;84:938–944.
   PubMed Web of Science ®Google Scholar
• Pellatt L, Hanna L, Brincat M, Galea R, Brain H, Whitehead S, Mason H. Granulosa cell production of antimüllerian hormone is increased in polycystic ovaries. J Clin Endocrinol Metab 2007;92:240–245.
   PubMed Web of Science ®Google Scholar
• Nader S, Diamanti-Kandarakis E. Polycystic ovary syndrome, oral contraceptives and metabolic issues: new perspectives and a unifying hypothesis. Hum Reprod 2007;22:317–322.
   PubMed Web of Science ®Google Scholar
• Streuli I, Fraisse T, Pillet C, Ibecheole V, Bischof P, de Ziegler D. Serum antimüllerian hormone levels remain stable throughout the menstrual cycle and after oral or vaginal administration of synthetic sex steroids. Fertil Steril 2008;90:395–400.
   PubMed Web of Science ®Google Scholar
• Somunkiran A, Yavuz T, Yucel O, Ozdemir I. Anti-Müllerian hormone levels during hormonal contraception in women with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol 2007;134:196–201.
   PubMed Web of Science ®Google Scholar
• Piltonen T, Morin-Papunen L, Koivunen R, Perheentupa A, Ruokonen A, Tapanainen JS. Serum anti-Müllerian hormone levels remain high until late reproductive age and decrease during metformin therapy in women with polycystic ovary syndrome. Hum Reprod 2005;20:1820–1826.
   PubMed Web of Science ®Google Scholar
• Zawadski JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome. In: Dunaif A, Givens JR, Haseltine FP, Merriam GE, editors. Polycystic ovary syndrome. Mass. USA: Blackwell Scientific Boston; 1992. pp 377–384.
   Google Scholar
• Baarends WM, Uilenbroek JT, Kramer P, Hoogerbrugge JW, van Leeuwen EC, Themmen AP, Grootegoed JA. Anti-Müllerian hormone and anti-Müllerian hormone type II receptor messenger ribonucleic acid expression in rat ovaries during postnatal development, the estrous cycle, and gonadotropin-induced follicle growth. Endocrinology 1995;136:4951–4962.
   PubMed Web of Science ®Google Scholar
• Visser JA, de Jong FH, Laven JS, Themmen AP. Anti-Müllerian hormone: a new marker for ovarian function. Reproduction 2006;131:1–9.
   PubMed Web of Science ®Google Scholar
• La Marca A, Stabile G, Artenisio AC, Volpe A. Serum anti-Müllerian hormone throughout the human menstrual cycle. Hum Reprod 2006;21:3103–3107.
   PubMed Web of Science ®Google Scholar
• Nestler JE. Metformin for the treatment of the polycystic ovary syndrome. N Engl J Med 2008;358:47–54.
   PubMed Web of Science ®Google Scholar
• Rotterdam ESHRE/ASRM-sponsored PCOS Consensus Workshop Group Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004;19:41–47.
   PubMed Web of Science ®Google Scholar
• Dunaif A, Futterweit W, Segal KR, Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in the polycystic ovary syndrome. Diabetes 1989;38:1165–1174.
   PubMed Web of Science ®Google Scholar
• Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implication for pathogenesis. Endocr Rev 1997;18:774–800.
   PubMed Web of Science ®Google Scholar
• Wu J, Zhu Y, Jiang Y, Cao Y. Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome. Gynecol Endocrinol 2008;24:392–398.
   PubMed Web of Science ®Google Scholar
• Luque-Ramírez M, Alvarez-Blasco F, Botella-Carretero JI, Martínez-Bermejo E, Lasunción MA, Escobar-Morreale HF. Comparison of ethinyl-estradiol plus cyproterone acetate versus metformin effects on classic metabolic cardiovascular risk factors in women with the polycystic ovary syndrome. J Clin Endocrinol Metab 2007;92:2453–2456.
   PubMed Web of Science ®Google Scholar
• Carlsen SM, Vanky E, Fleming R. Anti-Müllerian hormone concentrations in androgen-suppressed women with polycystic ovary syndrome. Hum Reprod 2009;24:1732–1738.
   PubMed Web of Science ®Google Scholar